Shots:
- Bio-Thera Solutions expanded its partnership with Intas Pharmaceuticals for BAT2506, a proposed biosimilar of Simponi (golimumab), through an exclusive commercialization and licensing agreement for India
- BAT2506 is a proposed golimumab biosimilar by Bio-Thera. Golimumab, a human IgG1 monoclonal antibody, targets TNF-α to reduce key inflammatory markers such as CRP, IL-6, ICAM-1, MMP-3, and VEGF. The reference drug is approved in Canada for conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis
- The expanded collaboration combines Bio-Thera’s development capabilities with Intas’ commercial strength in India, aiming to improve access to high-quality biosimilars in immunology. The deal also strengthens Intas’ biologics portfolio and reflects both companies’ focus on advancing affordable, science-driven therapies in high-demand markets like India
Ref: PRNewsWire| Image: Bio-Thera and Intas Pharmaceuticals | Press Release
Related News:- Bio-Thera Collaborates with Intas Pharmaceuticals for the Commercialization of BAT2506 (Biosimilar, Simponi) Across Canada
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
